News &amp; Updates

Treatment with statins combined with immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors, is associated with improved survival in cancer patients, according to a study.

ICIs plus statins may extend survival in cancer patients

Two pivotal phase III trials show that a once-daily application of tapinarof cream 1% yields rapid treatment response – as indicated by the vIGA-AD™×BSA* composite score – in individuals with moderate-to-severe atopic dermatitis (AD).

Composite metric boosts tapinarof efficacy for AD

20 Mar 2025 by

Composite metric boosts tapinarof efficacy for AD

20 Mar 2025

Low-dose minocycline formulation works against papulopustular rosacea

The low-dose modified formulation of minocycline hydrochloride, DFD-29, appears to be safe and efficacious in the treatment of adults with moderate to severe papulopustular rosacea, according to data from the phase III MVOR-1 and MVOR-2 trials.

Low-dose minocycline formulation works against papulopustular rosacea

NAC protects against chemo-induced neuropathy

Treatment with oral N-acetylcysteine (NAC) 1,200 mg/day does not result in a significant reduction in the incidence or severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer, a recent study has shown.

NAC protects against chemo-induced neuropathy

GLP-1 RA use before endoscopy tied to low retained gastric contents

Patients taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly those with type 2 diabetes (T2D), have very low rates of retained gastric contents during endoscopy, as shown in a study.

GLP-1 RA use before endoscopy tied to low retained gastric contents

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

18 Mar 2025

Treatment with the combination of the immune checkpoint inhibitor tislelizumab plus low-dose nab-paclitaxel exerts promising antitumour activity in patients with very high risk non–muscle-invasive bladder cancer who are ineligible for or decline radical cystectomy, according to the results of the phase II TRUCE-02 trial.

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

18 Mar 2025

Lebrikizumab improves anxiety, depression symptoms in adolescents with AD

18 Mar 2025 by

Lebrikizumab improves anxiety and depression symptoms, as shown by PROMIS* scores, in patients with moderate-to-severe atopic dermatitis (AD), according to the ADore trial presented at AAAAI/WAO 2025.

Lebrikizumab improves anxiety, depression symptoms in adolescents with AD

18 Mar 2025

$Abaloparatide helps prevent fractures in most vulnerable postmenopausal women$

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

17 Mar 2025 by

Treatment with abaloparatide appears to reduce the incidence of fractures as well as improve bone mineral density (BMD) in the subgroup of postmenopausal women at highest risk of fracture, according to a post hoc analysis of the ACTIVE* study.

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

Exposure to acetaminophen (paracetamol) may contribute to poor outcomes in patients with acute viral hepatitis (AVH)-related acute liver failure (ALF), suggests a study.

Acetaminophen use tied to negative outcomes in hepatitis-related ALF

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients

The use of glucagon-like peptide 1 receptor agonists (GLP-1 RA), compared with metformin, results in a significant decrease in the incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the need for first-line glaucoma treatments in patients with type 2 diabetes (T2D), reports a study.

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients